Main Street Research LLC Has $800,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Main Street Research LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 86.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 11,338 shares of the company's stock after selling 74,465 shares during the period. Main Street Research LLC's holdings in Novo Nordisk A/S were worth $800,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Bridges Investment Management Inc. lifted its position in shares of Novo Nordisk A/S by 3.4% in the first quarter. Bridges Investment Management Inc. now owns 7,550 shares of the company's stock worth $524,000 after purchasing an additional 250 shares in the last quarter. Moloney Securities Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 78.2% during the 1st quarter. Moloney Securities Asset Management LLC now owns 17,458 shares of the company's stock worth $1,212,000 after buying an additional 7,661 shares during the last quarter. Banque Pictet & Cie SA grew its holdings in shares of Novo Nordisk A/S by 1.2% in the 1st quarter. Banque Pictet & Cie SA now owns 36,625 shares of the company's stock valued at $2,543,000 after acquiring an additional 446 shares in the last quarter. Wealth Advisory Solutions LLC grew its holdings in shares of Novo Nordisk A/S by 7.9% in the 1st quarter. Wealth Advisory Solutions LLC now owns 42,537 shares of the company's stock valued at $2,954,000 after acquiring an additional 3,103 shares in the last quarter. Finally, Lakeside Advisors INC. increased its position in shares of Novo Nordisk A/S by 2.1% in the first quarter. Lakeside Advisors INC. now owns 19,050 shares of the company's stock valued at $1,323,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on NVO. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $1.80 on Thursday, reaching $71.49. The stock had a trading volume of 4,367,656 shares, compared to its average volume of 7,281,311. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The company has a market cap of $319.19 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64. The firm has a fifty day moving average of $70.25 and a two-hundred day moving average of $75.33. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $143.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion for the quarter. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.